EMPLOYMENT AGREEMENTEmployment Agreement • March 8th, 2018 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 13th day of November, 2017, between CRISPR Therapeutics, Inc., a Delaware corporation (the “Company”‘), and Michael Tomsicek (the “Executive” and, together with the Company, the “Parties” or each individually, a “Party”).
NON-QUALIFIED STOCK OPTION AGREEMENT FOR COMPANY EMPLOYEES UNDER THE CRISPR THERAPEUTICS AGNon-Qualified Stock Option Agreement • March 8th, 2018 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
Pursuant to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants to the Optionee named above an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value CHF 0.03 per share (the “Stock”) of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended.
INCENTIVE STOCK OPTION AGREEMENT UNDER THE CRISPR THERAPEUTICS AGIncentive Stock Option Agreement • March 8th, 2018 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
Pursuant to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants to the Optionee named above an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value CHF 0.03 per share (the “Stock”), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan.
RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES UNDER THE CRISPR THERAPEUTICS AGRestricted Stock Unit Award Agreement • March 8th, 2018 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
Pursuant to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants an award of the number of Restricted Stock Units listed above (an “Award”) to the Grantee named above. Each Restricted Stock Unit shall relate to one share of Common Stock, par value CHF 0.03 per share (the “Stock”) of the Company.
RESTRICTED STOCK UNIT AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE CRISPR THERAPEUTICS AGRestricted Stock Unit Award Agreement • March 8th, 2018 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
Pursuant to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants an award of the number of Restricted Stock Units listed above (an “Award”) to the Grantee named above. Each Restricted Stock Unit shall relate to one share of Common Stock, par value CHF 0.03 per share (the “Stock”) of the Company.
NON-QUALIFIED STOCK OPTION AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE CRISPR THERAPEUTICS AGNon-Qualified Stock Option Agreement • March 8th, 2018 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
Pursuant to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants to the Optionee named above, who is a Director of the Company but is not an employee of the Company, an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value CHF 0.03 per share (the “Stock”), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended.
RESTRICTED STOCK AWARD AGREEMENT UNDER THE CRISPR THERAPEUTICS AGRestricted Stock Award Agreement • March 8th, 2018 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
Pursuant to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants a Restricted Stock Award (an “Award”) to the Grantee named above. Upon acceptance of this Award, the Grantee shall receive the number of shares of Common Stock, par value CHF 0.03 per share (the “Stock”) of the Company specified above, subject to the restrictions and conditions set forth herein and in the Plan. The Company acknowledges the receipt from the Grantee of consideration with respect to the par value of the Stock in the form of cash, past or future services rendered to the Company by the Grantee or such other form of consideration as is acceptable to the Administrator.
